Sensyne Health Plc Enters Into An Agreement With A Fortune 200 Company

  • Sensyne Health Plc (SENS) has entered into an agreement with a Fortune 200 company and a data infrastructure specialist to launch and scale its digital health products under licence in the U.S.
  • The company will develop Clinical AI-as-a-service solutions that will use AI (artificial intelligence) and prognostic analytics to help foil and manage a variety of chronic health conditions.
  • On 7th October 2019, at the time of writing, GMT 12:22 PM, SENS shares were trading at GBX 107.50, up by 5.00 points or 4.88 per cent against the previous day closing price.